This article first appeared on GuruFocus.

AstraZeneca (NYSE:AZN), the global oncology and biopharmaceutical company, fell approximately 1.3% to $158 Wednesday, even after its experimental COPD treatment delivered positive Phase 3 results. The muted response suggests investors want commercial proofnot just strong clinical data.

AstraZeneca Falls 1.3% Despite a 34% COPD Breakthrough AZN GF Value chart

Tozorakimab reduced moderate or severe flare-ups by 29% and 34% among former smokers in the OBERON and TITANIA trials, respectively. Benefits remained substantial across the broader patient groups, with reductions of roughly 30% and 29%. AstraZeneca’s announcement covered 2,306 patients and identified no new safety signal. The FDA has granted priority review, putting a regulatory decision on the calendar for the first quarter of 2027.

AstraZeneca Falls 1.3% Despite a 34% COPD Breakthrough AstraZeneca Falls 1.3% Despite a 34% COPD Breakthrough ยท us.finance.gurufocus

The company produced $30.7 billion in first-half revenue and $10.5 billion in core operating profit, implying a robust 34.2% margin. At $158, the shares sit 12.48% below the $180.52 GF Value estimate shown in the chart, signaling potential upside if the drug clears its remaining hurdles. Tozorakimab could give AstraZeneca another respiratory growth engine, but approval, pricing and real-world adoption will determine whether today’s clinical win becomes tomorrow’s earnings growth.